Sintx Technologies, Inc.

For Q2 2026, revenue was $452,000 versus $151,000 a year ago, up 199%; product revenue was $447,000 versus $100,000, up 347%; grant and contract revenue was $5,000 versus $51,000. Gross profit was $278,000 versus $57,000, and gross margin was 61.5% versus 37.7% last year. Net loss was $2.7 million, compared with $2.3 million in the prior-year quarter. For the first half of 2026, revenue was $832,000, product revenue was $747,000, gross profit was $422,000, and net loss was $5.5 million. Management expects Q3 2026 revenue of about $900,000 to $1.1 million and Q4 2026 revenue of about $1 million to $1.3 million.

Eric Olson framed the quarter as evidence that SINTX is moving from a development company toward a commercially focused biomaterials and medical technology platform. He emphasized three priorities: convert contract manufacturing demand into recognized revenue, build a disciplined commercial path for the SiNAPTIC Foot & Ankle Osteotomy Wedge System, and pursue licensing or strategic partnerships where SINTX does not need to build every capability internally. His tone was cautiously optimistic but grounded, repeatedly stressing that execution, cash discipline, and repeatable commercialization are now the standard.

Kevin Trask highlighted the hard numbers: Q2 revenue of $452,000, gross margin of 61.5%, operating expenses of $3.2 million, and net loss of $2.7 million. He said the gross margin improvement reflected higher-margin sales, favorable mix, and better pricing on certain OEM products, but warned margin can vary by product mix and timing. On liquidity, he said cash and equivalents were $3.6 million at June 30, 2026, inventory was $2.3 million, operating cash use was $5.3 million in the first half, financing provided $4.8 million, and the company expects to continue seeking equity and/or debt funding.

There was no live analyst Q&A in the transcript, so no specific external questions or follow-ups were asked. Management nonetheless addressed likely investor concerns by emphasizing that announced purchase orders are not the same as recognized revenue, that shipment timing can vary, and that the company still faces significant liquidity risk. They also cautioned that the new margin profile may not repeat each quarter and that future revenue depends on production, shipment timing, customer scheduling, and revenue recognition.